Diosgenin Attenuates Angiogenesis via Targeting Src/STAT3 Signaling Pathway to Treat Non-Small Cell Lung Cancer

Key Points

• Diosgenin significantly decreases angiogenesis in non-small cell lung cancer models, suggesting therapeutic potential.
• Key evidence shows a 50% reduction in angiogenic activity after treatment with diosgenin in vitro.
• Analysis of the src/stat3 signaling pathway reveals that diosgenin inhibits this pathway's activation effectively.
• This study highlights a promising avenue for treating non-small cell lung cancer through targeting specific molecular pathways.